The Pharma Data

NOVEMBER 29, 2020

29 , 2020 /PRNewswire/ — Gannex, a wholly owned company of Ascletis Pharma Inc. Prior to joining Gannex, Dr. Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. SHANGHAI , Nov. Wu , Founder, Chairman and CEO of Ascletis. ” About Ascletis.

Clinical Development 40

Clinical Development Disease Clinical Trials Therapies 40

Drug Target Review

SEPTEMBER 26, 2023

These cells demonstrate considerable promise for uncovering drug-induced perturbations to neuronal function such as seizure, and their use extends further to sedation, anti-epileptic drug discovery and modelling of neurological diseases. Another area in need of attention is central nervous system (CNS)-safety testing.

Drugs 111

Drugs FDA Disease Animal Testing 111

Drug Patent Watch

JANUARY 8, 2025

This comprehensive guide will walk you through the intricacies of optimizing your drug patent strategy, ensuring that your innovations are safeguarded and your market position is strengthened. Understanding the Basics of Drug Patents Before diving into the nuances of patent strategy, it’s crucial to grasp the fundamentals.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Licensing Licensing 52

The Pharma Data

NOVEMBER 26, 2020

27, 2020 /PRNewswire/ — BioInvent International AB ‘s (publ) (“BioInvent”) (OMXS: BINV) Extraordinary General Meeting (the “EGM”) today resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. LEXINGTON, Mass.–(

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. SAN DIEGO , Oct.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

Drug Target Review

FEBRUARY 10, 2025

Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies. My focus has always been on advancing novel medicines from research to clinical development. Over the years, Ive had the privilege of working on more than 25 different products, Bock shared.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

The Pharma Data

SEPTEMBER 16, 2020

16, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that data from its oncology pipeline in solid tumors will be presented during the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Sept. 19-21, 2020. 20, 2020 , from 2:25 p.m. – 21, 2020 , from 2:25 p.m. – 20, 2020, at?11:00

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

JANUARY 21, 2021

In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. Title: Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity Speaker: Jacqulyne P.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact. Cilta-cel also won a Breakthrough Therapy designation in China in August.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

New Drug Approvals

JULY 8, 2025

1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Clinical Trials: Pritelivir is currently in phase II clinical trials, with ongoing research into its effectiveness and safety.

Virus 62

Virus DNA Clinical Trials Treatment 62

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020. CET on November 5, 2020. and AC101 in clinical development by Shanghai Henlius Biotech Inc.).

Packaging 40

Packaging Clinical Development Disease Drugs 40

The Pharma Data

OCTOBER 28, 2020

Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s. 29, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. ROCHESTER, N.Y., Vaccinex, Inc.

Clinical Trials 40

Clinical Trials Treatment Disease Clinical Development 40

The Pharma Data

OCTOBER 22, 2020

The closing of the offering is expected to occur on or about October 27, 2020, subject to the satisfaction of customary closing conditions. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.

Pharmaceutical Companies 40

Pharmaceutical Companies Clinical Trials Clinical Development Pharmaceuticals 40

The Pharma Data

DECEMBER 14, 2020

14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 NEW YORK, Dec.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

The Pharma Data

DECEMBER 17, 2020

The trial remains on-track to complete enrollment of all 500 patients in the United States and Australia before the end of 2020, despite the worsening of the COVID-19 pandemic. In its Phase II clinical trial, TLC599 significantly reduced pain at and through every scheduled visit through six months. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

DECEMBER 13, 2020

Cancer Research UK has partnered with Hummingbird Bioscience to advance this novel antibody drug into clinical trials for the treatment of HER3-driven cancer. Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing revolutionary therapies against hard-to-drug targets for improved treatment outcomes.

Clinical Development 40

Clinical Development Clinical Trials Therapies Trials 40

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. That’s one finding from an early study that tested the injection drug, which mimics the effects of a natural hormone called fibroblast growth factor 21 (FGF21).

Drugs 52

Drugs Regulations Science Research 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. Piper Sandler 32nd Annual Healthcare Conference, November 30 – December 3, 2020.

Clinical Trials 40

Clinical Trials Trials Disease FDA 40

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

(NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. President and Chief Executive of Harpoon Therapeutics. “I

Treatment 52

Treatment FDA Clinical Trials Drugs 52

The Pharma Data

DECEMBER 15, 2020

16, 2020 02:47 UTC. Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50

FDA Approval 40

FDA Approval Disease Therapies Clinical Development 40

The Pharma Data

NOVEMBER 18, 2021

Gilead has been encouraged by early clinical data generated for each of the three programs. By concluding in early to all three programs now, Gilead and Arcus are suitable to accelerate the clinical development and advancement of these clinical- stage motes and grease the disquisition of treatment combinations across the portfolios.

Research 52

Research Clinical Development Small Molecule Packaging 52

The Pharma Data

OCTOBER 29, 2020

Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe. Cromos Pharma provides tailored and effective clinical trial solutions to support the development of drugs that transform healthcare. About Cromos Pharma www.cromospharma.com.

Clinical Trials 40

Clinical Trials Trials International Biosimilars 40

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

The Pharma Data

MAY 2, 2022

Nasdaq: BIIB) initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug being developed for MDD and postpartum depression (PPD).

Treatment 52

Treatment Drugs Clinical Pharmacology Clinical Development 52

The Pharma Data

OCTOBER 18, 2020

19, 2020 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) , for OPD5 – a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC).

FDA 40

FDA Drugs Pharmaceutical Companies Treatment 40

The Pharma Data

OCTOBER 31, 2020

1, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) ( Taiwan : 4157) announced today that U.S. Food and Drug Administration (“FDA”) has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B. TAIPEI, Taiwan , Nov. SOURCE TaiGen.

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

Metabolite Tales Blog

JANUARY 26, 2023

Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. “The executive vice president of research and development. “We THE WOODLANDS, Texas, Dec.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

The Pharma Data

DECEMBER 27, 2020

28, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial Authorization) application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab. CET on December 28, 2020.

Clinical Trials 52

Clinical Trials Clinical Development Trials Drugs 52

The Pharma Data

DECEMBER 16, 2020

17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. OS is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. . HOUSTON , Dec. About CNS Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Metabolite Tales Blog

APRIL 4, 2023

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. Tapinarof is metabolised by multiple pathways including oxidation, glucuronidation, and sulfation.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. .

Clinical Development 40

Clinical Development Doctors Drug Development International 40

Metabolite Tales Blog

JULY 5, 2023

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. However, in the quest to tackle challenging disease targets with difficult drug binding sites, there is revived interest in developing this compound type to offer unique solutions.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Armata Pharmaceuticals , Inc. Food and Drug Administration (FDA) has cleared Armata’s IND to initiate a clinical trial of its lead therapeutic candidate, AP-PA02, in Pseudomonas aeruginosa infections. . . MARINA DEL REY, Calif. , Forward Looking Statements.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Drugs 52